Cerebrospinal α‐Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cerebrospinal α‐Synuclein Oligomers Reflect Disease Motor Severity in
DeNoPa
Longitudinal Cohort
Authors
Keywords
-
Journal
MOVEMENT DISORDERS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-05-12
DOI
10.1002/mds.28611
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers
- (2020) Nour K. Majbour et al. Translational Neurodegeneration
- Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression
- (2020) Brit Mollenhauer et al. MOVEMENT DISORDERS
- Parkinson’s disease biomarkers based on α‐synuclein
- (2019) Muneera Fayyad et al. JOURNAL OF NEUROCHEMISTRY
- CSF and blood biomarkers for Parkinson's disease
- (2019) Lucilla Parnetti et al. LANCET NEUROLOGY
- Longitudinal analyses of cerebrospinal fluid α‐Synuclein in prodromal and early Parkinson's disease
- (2019) Brit Mollenhauer et al. MOVEMENT DISORDERS
- Evolution of cerebrospinal fluid total α-synuclein in Parkinson's disease
- (2018) Marthe Gurine Førland et al. PARKINSONISM & RELATED DISORDERS
- Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa)
- (2018) Brit Mollenhauer et al. MOVEMENT DISORDERS
- α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies
- (2018) Inger van Steenoven et al. MOVEMENT DISORDERS
- Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study
- (2017) Anette Schrag et al. LANCET NEUROLOGY
- Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease
- (2017) Jean-Pierre Trezzi et al. MOVEMENT DISORDERS
- Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls
- (2017) Brit Mollenhauer et al. NEUROLOGY
- Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease
- (2017) Nour K. Majbour et al. Scientific Reports
- Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
- (2016) Nour K. Majbour et al. Molecular Neurodegeneration
- Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression
- (2016) Nour K. Majbour et al. MOVEMENT DISORDERS
- Monitoring of 30 marker candidates in early Parkinson disease as progression markers
- (2016) Brit Mollenhauer et al. NEUROLOGY
- MDS clinical diagnostic criteria for Parkinson's disease
- (2015) Ronald B. Postuma et al. MOVEMENT DISORDERS
- Minimal clinically important difference on the Motor Examination part of MDS-UPDRS
- (2015) Krisztina Horváth et al. PARKINSONISM & RELATED DISORDERS
- A Practical Guide to Immunoassay Method Validation
- (2015) Ulf Andreasson et al. Frontiers in Neurology
- Phosphorylated α-synuclein in Parkinson’s disease: correlation depends on disease severity
- (2015) Tessandra Stewart et al. Acta Neuropathologica Communications
- Cerebrospinal Fluid α-Synuclein Predicts Cognitive Decline in Parkinson Disease Progression in the DATATOP Cohort
- (2014) Tessandra Stewart et al. AMERICAN JOURNAL OF PATHOLOGY
- CSF biomarkers and clinical progression of Parkinson disease
- (2014) S. Hall et al. NEUROLOGY
- Low clinical diagnostic accuracy of early vs advanced Parkinson disease: Clinicopathologic study
- (2014) C. H. Adler et al. NEUROLOGY
- Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort
- (2013) B. Mollenhauer et al. NEUROLOGY
- Expanded and independent validation of the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)
- (2012) Pablo Martinez-Martin et al. JOURNAL OF NEUROLOGY
- α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study
- (2011) Brit Mollenhauer et al. LANCET NEUROLOGY
- Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies
- (2010) Brit Mollenhauer et al. Biomarkers in Medicine
- Systematic review of levodopa dose equivalency reporting in Parkinson's disease
- (2010) Claire L. Tomlinson et al. MOVEMENT DISORDERS
- Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results
- (2008) Christopher G. Goetz et al. MOVEMENT DISORDERS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started